CN104146975A - Montelukast sodium chewable tablet, preparation method and determination method of dissolution rate - Google Patents
Montelukast sodium chewable tablet, preparation method and determination method of dissolution rate Download PDFInfo
- Publication number
- CN104146975A CN104146975A CN201410424525.8A CN201410424525A CN104146975A CN 104146975 A CN104146975 A CN 104146975A CN 201410424525 A CN201410424525 A CN 201410424525A CN 104146975 A CN104146975 A CN 104146975A
- Authority
- CN
- China
- Prior art keywords
- solution
- dissolution
- chewable tablet
- menglusitena
- take
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940068682 chewable tablet Drugs 0.000 title claims abstract description 63
- 239000007910 chewable tablet Substances 0.000 title claims abstract description 63
- 238000004090 dissolution Methods 0.000 title claims abstract description 53
- 238000000034 method Methods 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 32
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 title abstract description 8
- 229960001951 montelukast sodium Drugs 0.000 title abstract description 8
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims abstract description 33
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims abstract description 33
- 238000004132 cross linking Methods 0.000 claims abstract description 32
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 30
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 29
- 239000001768 carboxy methyl cellulose Substances 0.000 claims abstract description 29
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 19
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 16
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 16
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 16
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 16
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 15
- 229930195725 Mannitol Natural products 0.000 claims abstract description 15
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 15
- 239000000594 mannitol Substances 0.000 claims abstract description 15
- 235000010355 mannitol Nutrition 0.000 claims abstract description 15
- 241000167854 Bourreria succulenta Species 0.000 claims abstract description 13
- 235000019693 cherries Nutrition 0.000 claims abstract description 13
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims abstract description 8
- 239000002904 solvent Substances 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 33
- 229960005127 montelukast Drugs 0.000 claims description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- 239000000047 product Substances 0.000 claims description 18
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 16
- BXAPDQHYAQOAHO-UHFFFAOYSA-M sodium;dodecyl sulfate;phosphoric acid Chemical compound [Na+].OP(O)([O-])=O.CCCCCCCCCCCCOS(O)(=O)=O BXAPDQHYAQOAHO-UHFFFAOYSA-M 0.000 claims description 15
- 238000003556 assay Methods 0.000 claims description 13
- 239000008187 granular material Substances 0.000 claims description 13
- 239000012738 dissolution medium Substances 0.000 claims description 12
- 238000005550 wet granulation Methods 0.000 claims description 12
- 239000008366 buffered solution Substances 0.000 claims description 11
- 235000009508 confectionery Nutrition 0.000 claims description 11
- 229950005770 hyprolose Drugs 0.000 claims description 11
- 239000013558 reference substance Substances 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- 239000002953 phosphate buffered saline Substances 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 5
- 238000010790 dilution Methods 0.000 claims description 5
- 239000012895 dilution Substances 0.000 claims description 5
- 238000011978 dissolution method Methods 0.000 claims description 5
- -1 montelukast hexanamine salt Chemical class 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 claims description 4
- 238000010812 external standard method Methods 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims description 3
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 4
- 108010011485 Aspartame Proteins 0.000 abstract description 2
- 239000000605 aspartame Substances 0.000 abstract description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 abstract description 2
- 235000010357 aspartame Nutrition 0.000 abstract description 2
- 229960003438 aspartame Drugs 0.000 abstract description 2
- 229940071676 hydroxypropylcellulose Drugs 0.000 abstract 2
- 238000001514 detection method Methods 0.000 abstract 1
- 229960001855 mannitol Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 description 11
- 238000002386 leaching Methods 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000006399 behavior Effects 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 239000000654 additive Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000004518 granules dosage form Substances 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 239000003605 opacifier Substances 0.000 description 2
- 238000009702 powder compression Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
- 102000010918 Cysteinyl leukotriene receptors Human genes 0.000 description 1
- 108050001116 Cysteinyl leukotriene receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to the field of medicinal preparations and particularly relates to a montelukast sodium chewable tablet, apreparation method and a determination method of a dissolution rate. Raw materials of the montelukast sodium chewable tablet comprise montelukast sodium, mannitol, microcrystalline cellulose, hydroxy propyl cellulose, crosslinking sodium carboxymethylcellulose, aspartame, ferric oxide, magnesium stearate and cherry essence. The hydroxy propyl cellulose is prepared into a solution with a mass percentage content being 6-8% through water being a solvent and a disintegrating agent is prepared through a wet process of an internal addition method. The montelukast sodium chewable tablet is significantly increased in disintegrating speed and in-vitro dissolution rate. By means of a dissolution curve detection method, quality differences among products in each batch can be effectively distinguished. Differences between products in each batch can be reduced better and a quality risk of the products can be controlled in a controllable range.
Description
Technical field
The present invention relates to field of medicaments, particularly a kind of Menglusitena chewable tablet and preparation method thereof and dissolving-out method.
Background technology
Montelukast is nonsteroidal anti-inflammatory drug of new generation, is a kind of selectivity LTRA.This product has affinity and the selectivity of height to CysLT1 receptor (Leukotrienes sputum receptor 1), the proinflammatory effect Control of asthma outbreak of blocking-up leukotriene and without any receptor agonist activity, its Clinical efficacy and safety for the treatment of childhood asthma is confirmed.
Menglusitena is the sodium-salt form of montelukast, and less stable is unstable to strong acid, illumination, easily decompose, and meets oxidant oxidizable.Menglusitena is one of best-selling treating asthma medicine in the world at present, and over 1998, in the listing of a plurality of countries and regions, existing dosage form has Film coated tablets, chewable tablet, oral cavity disintegration tablet, granule.In technique, take direct powder compression and wet granulation as main.Though direct powder compression can be simplified production technology, shorten the production cycle.But the mobile phase of powder is poor, very high to the requirement of adjuvant, under the condition without additives in prescription, easily cause content to decline, many drawbacks such as related substance increase.And the stripping of finished product is on the low side compared with wet granulation.Current wet granulations that adopt, slice, thin piece external form that this method is produced is better, compressibility is high, stripping good, bioavailability is high, adds the stability that applicable additives improve product more.But mainly there is at present following problem: 1) Menglusitena is shown in that light easily produces photodegradative cis-isomer impurity, has relatively high expectations to production environment.2) part wet granulation technology adopts ethanol as adhesive solvent, because Menglusitena is very easily dissolved in the decline that alcohols solvent causes main content, affects quality and the curative effect of product.
CN101732268A (CN201010003871.0) discloses a kind of montelukast sodium tablet, it is comprised of Menglusitena, microcrystalline Cellulose, carboxymethyl starch sodium, iron oxide red, lubricant, fluidizer and binding agent, and wherein lubricant is magnesium stearate or zinc stearate; Fluidizer is micropowder silica gel, talcous a kind of or two kinds; Binding agent is selected from one or more in polyvinylpyrrolidone-vinyl acetate co-polymer, sodium carboxymethyl cellulose and polyvinylpyrrolidone.This invention adopts iron oxide red coloring agent and dry method polyvinyl pyrrolidone-vinyl acetate co-polymer to solve the problem that in preparation process, Menglusitena is shown in photo-labile, direct compression after employing dry granulation.
CN101773481A (CN201010003886.7) discloses a kind of Menglusitena chewable tablet, it is characterized in that it is composed of the following components: Menglusitena, microcrystalline Cellulose, mannitol, 4%PVPK30 alcoholic solution, zinc stearate and opacifier, described opacifier is iron oxide red, iron oxide yellow or titanium dioxide.
CN1961867A (CN200610151038.4) discloses a kind of montelukast sodium granules type, wherein contains: (1) Menglusitena, (2) auxiliary additive is the additive of preparing the pharmaceutically acceptable granule dosage form of granule dosage form.
Application for a patent for invention prospectus CN101365450A discloses the stabilised pharmaceutical preparation of Menglusitena, the chewable tablet that contains Menglusitena is wherein disclosed, disclosed chewable tablet comprises Menglusitena, hydroxypropyl cellulose, sodium starch glycolate, mannitol, coloring agent (as ferrum oxide), additional sweeting agent, flavouring agent and magnesium stearate, does not contain microcrystalline Cellulose.
Publication number is the patent of CN103239450A, by adding the additives such as sodium hydroxide, sodium carbonate to improve stability and the dissolubility of tablet in prescription.This patent is thought Menglusitena indissoluble in gastrointestinal sour environment, can improve the alkaline microenvironment of oral solid formulation by additives, to improve the dissolution rate of medicine, promotes medicine absorption in vivo.
The most patents that retrieved, that mode by the adjuvant of Menglusitena chewable tablet being adjusted or being added additives is to improve preparation stability or stripping, do not relate to the improvement to disintegration rate, and do not relate to the improvement of Menglusitena chewable tablet dissolving-out method.
Summary of the invention
The object of this invention is to provide a kind of Menglusitena chewable tablet and preparation method thereof
Another object of the present invention is to provide a kind of assay method of Menglusitena chewable tablet dissolution.
In order to realize object of the present invention, the present invention adopts following technical scheme: a kind of Menglusitena chewable tablet, is prepared from by the raw material that comprises following weight portion:
It is that solvent is mixed with the solution that quality percentage composition is 6-8% that described hydroxypropyl cellulose adopts water.
In order to realize better tabletting and result of extraction, the present invention preferably adopts following technical scheme, and a kind of Menglusitena chewable tablet, is prepared from by the raw material that comprises following weight portion:
The present invention finds after deliberation, only need by 95% ethanol, change the solvent of preparation binding agent into water, and the disintegration rate of Menglusitena chewable tablet and dissolution in vitro just can significantly improve.And MK chewable tablet of the present invention all can be realized with former and grind the similar stripping behavior of medicine Singulair that contrasts in 0.4-0.6% (mass volume ratio) sodium lauryl sulphate phosphate buffered solution, and can effectively distinguish that production technology changes and formulation and technology changes the stripping impact that product is caused, stability and former bioequivalence of grinding product between having guaranteed batch.
Another technical scheme of the present invention, the preparation method that Menglusitena of the present invention is chewed, comprises the following steps:
(1), under the condition of lucifuge, Menglusitena crude drug, magnesium stearate, red ferric oxide, mannitol, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, aspartame, cherry essence are sieved respectively;
(2) take hyprolose and add purified water, be stirred to and dissolve completely, being mixed with quality percentage composition is 6-8% aqueous solution;
(3) by the Menglusitena having sieved, mannitol, microcrystalline Cellulose, partial cross-linked sodium carboxymethyl cellulose, red ferric oxide mix homogeneously in wet granulation equipment, the hyprolose aqueous solution that adds step (2) to be mixed with, wet granulation, granulate;
(4) wet granular step (3) being made, through fluidized drying, makes moisture Control below 1.5%, granulate;
(5) add cross-linking sodium carboxymethyl cellulose, cherry essence, the A Siba of surplus sweet, magnesium stearate mix after tabletting.
Preparation method disintegrating agent of the present invention (cross-linking sodium carboxymethyl cellulose) adopts and in step (3) and (5) two steps of step, adds respectively, and this kind of preparation method can effectively improve the dissolution of medicine.
Concrete, step (1) is crossed 80-100 mesh sieve by Menglusitena crude drug, magnesium stearate, red ferric oxide; Mannitol, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, A Siba are sweet, cherry essence is crossed 60-80 mesh sieve.
Concrete, the 40-60% that the addition of the described cross-linking sodium carboxymethyl cellulose of step (3) is all cross-linking sodium carboxymethyl celluloses, preferably 50%.
Concrete, 30 mesh sieve granulate for step (3); 20 mesh sieve granulate for step (4); Step (5) is mixed 15-20min in three-dimensional motion mixer.
Concrete, in step (4), wet granular is put to fluidized drying and can be selected the arbitrary scheme in prior art scheme, preferably adopt following technical scheme: in fluidization drying apparatus, 40 ℃ of-45 ℃ of fluidized drying 30min-40min.
Concrete, the described mixing of step (5) can be selected the arbitrary scheme in prior art scheme, preferably adopts following technical scheme: in three-dimensional motion mixer, mix 15-20min.
Concrete, the described tabletting of step (5) can be selected the arbitrary scheme in prior art scheme, preferably adopts following technical scheme: adopt high speed rotating tablet machine tabletting, the heavily about 0.3g of sheet, pressure 60-75N, diameter 10mm.
In addition, even if experimenter of the present invention finds that in prescription research process existing dissolving-out method still can show good stripping curve and stripping behavior under the condition of change prescription, processing parameter.Such dissolving-out method has brought certain risk to the control of the control of product quality and production technology.The present invention, according to experiment experience in the past, on existing methodical basis, has made improvement to dissolving-out method, has improved selectivity and the differentiation power of dissolving-out method.
Another technical scheme of the present invention, the assay method of Menglusitena chewable tablet dissolution, according to two appendix XC dissolution method the second methods of Chinese Pharmacopoeia version in 2010, the sodium lauryl sulphate phosphate buffered solution that the mass volume ratio of take is 0.4-0.6% is dissolution medium.Mass volume ratio herein refers to the mass volume ratio of sodium lauryl sulphate and phosphate buffer.
Concrete, the assay method of Menglusitena chewable tablet dissolution of the present invention comprises the following steps:
(1) getting 5mg chewable tablet, to take the sodium lauryl sulphate phosphate buffered solution that 900ml mass volume ratio is 0.4-0.6% be dissolution medium, rotating speed is per minute 50 to turn, during respectively at 5min, 10min, 15min, 20min, 30min, sample 10ml, filter, get subsequent filtrate as need testing solution; Separately get reference substance 15mg, add dissolve with methanol and be diluted to 50ml, shake up, after shaking up, get 2ml solution, add mass volume ratio 0.4-0.6% sodium lauryl sulphate phosphate buffered saline(PBS) dissolved dilution to 100ml, in contrast product solution;
(2) get need testing solution and the reference substance solution employing high performance liquid chromatography of step (1) gained, take phenyl bonded silica gel as filler, take 0.2% trifluoroacetic acid aqueous solution (mass volume ratio) and 0.2% trifluoroacetic acid acetonitrile solution (mass volume ratio) by volume as the mixed solution of 1: 1 is mobile phase, by external standard method with calculated by peak area dissolution.
Preferably, step (1) is got 5mg chewable tablet, and to take the sodium lauryl sulphate phosphate buffered solution that 900ml mass volume ratio is 0.5% be dissolution medium, rotating speed is per minute 50 to turn, during respectively at 5min, 10min, 15min, 20min, 30min, sample 10ml, filter, get subsequent filtrate as need testing solution; Separately get reference substance 15mg, add dissolve with methanol and be diluted to 50ml, after shaking up, get 2ml solution, add mass volume ratio 0.5% sodium lauryl sulphate phosphate buffered saline(PBS) dissolved dilution to 100ml, in contrast product solution.
The described reference substance of step (1) is chosen a kind of in montelukast hexanamine salt, montelukast acid, Menglusitena, preferably montelukast hexanamine salt.
Concrete, when step (2) adopts high performance liquid chromatography, flow velocity is 0.8-1.0ml/min; Column temperature is 48-52 ℃, and sampling volume is 48-52 μ l.
Dissolving-out method of the present invention can show good stripping curve and stripping behavior, thereby can control the quality of product at change prescription, the equal of processing parameter all existing products.Under poor prescription and technological parameter, stripping curve and behavior performance are poor, and under normal process and parameter, stripping curve and behavior show up to specification, and the dissolving-out method of existing standard can not be distinguished.
The assay method of Menglusitena chewable tablet dissolution provided by the invention can also be for measuring tablet and the granule containing montelukast sodium raw materials.
Accompanying drawing explanation
Fig. 1 is the stripping curve that Singulair and embodiment 4 utilize dissolution determination method of the present invention to measure;
Fig. 2 is the stripping curve of measuring with dissolution determination method of the present invention at different disintegrating agent consumption prescription condition diarrhea;
Fig. 3 is the stripping curve comparison of measuring with dissolution determination method of the present invention at different-grain diameter raw material prescription condition diarrhea;
Fig. 4 is Singulair and embodiment 4 stripping curve under standard leaching condition abroad;
Fig. 5 is the stripping curve under standard leaching condition abroad under different disintegrating agent consumption prescription conditions;
Fig. 6 is the stripping curve under standard leaching condition abroad under different-grain diameter raw material prescription condition.
The specific embodiment
Following examples are used for illustrating the present invention, but are not used for limiting the scope of the invention.
Embodiment 1-embodiment 3
In embodiment 1-embodiment 3, Menglusitena chewable tablet comprises that raw material is as follows:
| Embodiment 1 | Embodiment 2 | Embodiment 3 |
| Menglusitena 3g | Menglusitena 2g | Menglusitena 1g |
| Mannitol 128g | Mannitol 75.25g | Mannitol 42.6g |
| Microcrystalline Cellulose 22g | Microcrystalline Cellulose 14.75 | Microcrystalline Cellulose 7.5g |
| Hydroxypropyl cellulose 2.33g | Hydroxypropyl cellulose 1.5g | Hydroxypropyl cellulose 0.8g |
| Cross-linking sodium carboxymethyl cellulose 9g | Cross-linking sodium carboxymethyl cellulose 6g | Cross-linking sodium carboxymethyl cellulose 3g |
| The sweet 0.3g of A Siba | The sweet 0.2g of A Siba | The sweet 0.1g of A Siba |
| Red ferric oxide 0.9g | Red ferric oxide 0.9g | Red ferric oxide 0.3g |
| Magnesium stearate 0.6g | Magnesium stearate 0.6g | Magnesium stearate 0.2g |
| Cherry essence 0.45g | Cherry essence 0.45g | Cherry essence 0.15g |
The preparation method of embodiment 1 Menglusitena chewable tablet comprises the following steps:
(1), under the condition of lucifuge, Menglusitena crude drug, magnesium stearate, red ferric oxide are crossed to 100 mesh sieves; Mannitol, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, A Siba are sweet, cherry essence is crossed 80 mesh sieves;
(2) take hyprolose and add purified water, be stirred to and dissolve completely, be mixed with 8% hyprolose adhesive aqueous solution;
(3) by the Menglusitena having sieved, mannitol, microcrystalline Cellulose, partial cross-linked sodium carboxymethyl cellulose (in mass ratio, account for all cross-linking sodium carboxymethyl celluloses 60%), red ferric oxide mix homogeneously in wet granulation equipment, the 8% hyprolose aqueous solution that adds step (2) to be mixed with, wet granulation, with 30 mesh sieve granulate;
(4) wet granular step (3) being made is put into fluidized bed drying equipment, and dry 30min, makes moisture Control below 1.5%, 20 mesh sieve granulate for dried particles at 40 ℃;
(5) add that surplus cross-linking sodium carboxymethyl cellulose, cherry essence, A Siba are sweet, magnesium stearate is mixed 15min in three-dimensional motion mixer, with Highspeedrotarytabletpress, be pressed into tablet.
The preparation method of embodiment 2 MK chewable tablet is compared with embodiment 1, and difference is: step (2) takes hyprolose and adds purified water, is stirred to and dissolves completely, and being mixed with quality percentage composition is 6% aqueous solution.
The preparation method of embodiment 3 MK chewable tablet is compared with embodiment 1, and difference is: the addition of the described cross-linking sodium carboxymethyl cellulose of step (3) is all cross-linking sodium carboxymethyl celluloses 40%.
Experimental example 1:
This experimental example is according to dissolution determination method of the present invention, and the Menglusitena chewable tablet of embodiment 1-embodiment 3 preparations is carried out to the research of stripping curve.
The dissolution determination method of embodiment 1, comprises the following steps:
(1) according to two appendix XC dissolution method the second methods of Chinese Pharmacopoeia version in 2010, getting chewable tablet a slice (5mg/ sheet), to take 0.4% (mass volume ratio) sodium lauryl sulphate phosphate buffered solution (pH=6.8) 900ml be dissolution medium, rotating speed is per minute 50 to turn, during respectively at 5min, 10min, 15min, 20min, 30min, sample 10ml, filter, get subsequent filtrate as need testing solution, equivalent is supplemented synthermal fresh dissolution medium; Separately get montelukast hexanamine salt 15mg, add dissolve with methanol and be diluted to 50ml, shake up, get above-mentioned solution 2ml, add 0.5% sodium lauryl sulphate phosphate buffered solution dissolved dilution to 100ml, in contrast product solution;
(2) according to two appendix VD of Chinese Pharmacopoeia version in 2010, get step (1) need testing solution and reference substance solution and adopt high performance liquid chromatography, take phenyl bonded silica gel as filler, the mixed solution that 0.2% trifluoroacetic acid aqueous solution and 0.2% trifluoroacetic acid acetonitrile solution are 1: 1 by volume of take is mobile phase, and flow velocity is 0.9ml/min; Column temperature is 50 ℃, and sampling volume is 50 μ l, by external standard method with calculated by peak area dissolution.
The assay method of embodiment 2 dissolutions is compared with embodiment 1, and difference is: by mass volume ratio, take containing 0.6% sodium lauryl sulphate phosphate buffered solution is dissolution medium.
The assay method of embodiment 3 dissolutions is compared with embodiment 1, and difference is: by mass volume ratio, take containing 0.5% sodium lauryl sulphate phosphate buffered solution is dissolution medium.
The dissolution of table 1 embodiment 1-embodiment 3 Menglusitena chewable tablet
The disintegration rate of table 2 embodiment 1-embodiment 3 Menglusitena chewable tablet
| Sample | Embodiment 1 | Embodiment 2 | Embodiment 3 |
| Disintegration | ＜3min | ＜3min | ＜4min |
Embodiment 4
In the present embodiment, Menglusitena chewable tablet comprises the raw material of following weight:
In the present embodiment, the preparation method of Menglusitena chewable tablet comprises the following steps:
(1), under the condition of lucifuge, Menglusitena crude drug, magnesium stearate, red ferric oxide are crossed to 100 mesh sieves; Mannitol, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, A Siba are sweet, cherry essence is crossed 80 mesh sieves;
(2) take hyprolose and add purified water, be stirred to and dissolve completely, be mixed with 8% hyprolose adhesive aqueous solution;
(3) by the Menglusitena having sieved, mannitol, microcrystalline Cellulose, 9.6g cross-linking sodium carboxymethyl cellulose, red ferric oxide mix homogeneously in wet granulation equipment, the 8% hyprolose aqueous solution that adds step (2) to be mixed with, wet granulation, with 30 mesh sieve granulate;
(4) wet granular step (3) being made is put into fluidized bed drying equipment, and dry 30min, makes moisture Control below 1.5%, 20 mesh sieve granulate for dried particles at 40 ℃;
(5) add cross-linking sodium carboxymethyl cellulose, cherry essence, the A Siba of surplus 9.6g sweet, magnesium stearate mixes 15min in three-dimensional motion mixer, with Highspeedrotarytabletpress, is pressed into tablet.
Embodiment 5
In the raw material of the present embodiment chewable tablet, except the consumption of cross-linking sodium carboxymethyl cellulose is different from embodiment 1, the composition of remainder and consumption are all identical with embodiment 4.The consumption of cross-linking sodium carboxymethyl cellulose is 4.8g in the present embodiment.The prescription sample that departs from scope that this embodiment designs for experimenter is checking dissolving-out method.
The preparation method that the present embodiment is concrete, except adding cross-linking sodium carboxymethyl cellulose 2.4g in step (3), step (5) adds outside cross-linking sodium carboxymethyl cellulose 2.4g, and all the other steps are also identical with embodiment 1.
Embodiment 6
In the raw material of the present embodiment chewable tablet, except the consumption of cross-linking sodium carboxymethyl cellulose is different from embodiment 1, the composition of remainder and consumption are all identical with embodiment 4.The consumption of cross-linking sodium carboxymethyl cellulose is 9.6g in the present embodiment.
The preparation method that the present embodiment is concrete, except adding cross-linking sodium carboxymethyl cellulose 4.8g in step (3), step (5) adds outside cross-linking sodium carboxymethyl cellulose 4.8g, and all the other steps are also identical with embodiment 1.
Embodiment 7
The raw material of the present embodiment chewable tablet forms with embodiment 1.
The preparation method of the present embodiment, except the Menglusitena mean diameter of using is 30 μ m, is about to Menglusitena and crosses outside 380 mesh sieves, and all the other preparation process are consistent with embodiment 4.
Embodiment 8
The raw material of the present embodiment chewable tablet forms with embodiment 1.
The preparation method of the present embodiment, except the Menglusitena mean diameter of using is 150 μ m, is about to Menglusitena and crosses outside 80 mesh sieves, and all the other preparation process are consistent with embodiment 4.
Experimental example 2
The present embodiment has been measured the dissolution of the chewable tablet of embodiment 4-embodiment 8 preparations.Wherein the Singulair in table 1 and Fig. 1 is commercially available Menglusitena chewable tablet, and manufacturer is MerckSharp & Dohme Ltd. (U.K.), specification 5mg/ sheet; Embodiment 4 is Menglusitena chewable tablet provided by the invention, and Singulair and embodiment 4 dissolutions the results are shown in Table 3 and Fig. 1; Embodiment 5 and embodiment 6 are the dissolution of crucial adjuvant (cross-linking sodium carboxymethyl cellulose) consumption Menglusitena chewable tablet while changing, and it the results are shown in Table 4 and Fig. 2; Menglusitena chewable tablet dissolution when embodiment 7 and embodiment 8 change for Menglusitena particle diameter, it the results are shown in Table 5 and Fig. 3.
Table 3 Singulair and the dissolution of embodiment 4 under leaching condition of the present invention
Dissolution under the chewable tablet of the different disintegrating agent consumptions of table 4 under leaching condition of the present invention
The dissolution of the chewable tablet of table 5 different material particle diameter under leaching condition of the present invention
Table 6 Singulair and embodiment comparison 4 disintegration
| Sample title | Singulair | Embodiment 1 sample |
| Complete disintegration | ＜5min | ＜3min |
By table 3 and Fig. 1, can be found out, under identical condition determination, the dissolution of Menglusitena chewable tablet provided by the invention is greater than Singulair, and in 15min, Menglusitena chewable tablet dissolution of the present invention is greater than 85%, meets the requirement of chewable tablet correlation technique.
, in the process that the dissolution of Menglusitena chewable tablet and Singulair is measured, find meanwhile, the disintegrate completely in 3 minutes of embodiment 4 samples, disintegration rate is faster than Singulair.
Again, from table 3-table 5 and Fig. 1-Fig. 3, dissolution determination method of the present invention can be distinguished different prescriptions preferably and technique causes the mass discrepancy between product, can better control product quality attribute.
Comparative example
This comparative example is the dissolution in vitro experimental technique with reference to existing external report, carries out the research of the Menglusitena chewable tablet In Vitro Dissolution curve of embodiment 4-embodiment 8 preparations.
Concrete, in this comparative example, Menglusitena chewable tablet dissolution in vitro experimental technique is as follows:
(1) lucifuge operation, get Menglusitena chewable tablet a slice (5mg/ sheet) of embodiment 4-embodiment 8 preparations according to dissolution method (two appendix XC dissolution method the second methods of Chinese Pharmacopoeia version in 2010), take respectively that to contain 0.5% (mass volume ratio) lauryl sodium sulfate aqueous solution 900ml be dissolution medium, rotating speed is per minute 50 to turn, respectively at 5min, 10min, 15min, 20min, during 30min, sample 10ml, filter, get subsequent filtrate as need testing solution, equivalent is supplemented synthermal fresh dissolution medium, i.e. 0.5% lauryl sodium sulfate aqueous solution, separately get montelukast hexanamine salt 15mg, add dissolve with methanol and be diluted to 50ml, shake up, get above-mentioned solution 2ml, add 0.5% lauryl sodium sulfate aqueous solution and be diluted to 100ml, in contrast product solution,
(2) according to two appendix V D of Chinese Pharmacopoeia version in 2010, get step (1) need testing solution and reference substance solution and adopt high performance liquid chromatography, take phenyl bonded silica gel as filler, the mixed solution that 0.2% trifluoroacetic acid aqueous solution and 0.2% trifluoroacetic acid acetonitrile solution are 1: 1 by volume of take is mobile phase, and flow velocity is 0.9ml/min; Column temperature is 50 ℃, and sampling volume is 50 μ l, by external standard method with calculated by peak area dissolution.
This comparative example has been measured the dissolution of the chewable tablet of embodiment 4-embodiment 8 preparations, wherein the Singulair in table 7 and Fig. 4 is commercially available Menglusitena chewable tablet, manufacturer is Merck Sharp & Dohme Ltd. (U.K.), specification 5mg/ sheet, embodiment 4 is Menglusitena chewable tablet provided by the invention, and its dissolution the results are shown in Table 7 and Fig. 4; Embodiment 5 and embodiment 6 are the dissolution of crucial adjuvant (cross-linking sodium carboxymethyl cellulose) consumption chewable tablet while changing, and it the results are shown in Table 8 and Fig. 5; Dissolution when embodiment 7 and embodiment 8 change for Menglusitena particle diameter, its result is table 9 and Fig. 6.
Table 7 Singulair and embodiment 4 be the dissolution under standard leaching condition abroad
Dissolution under standard leaching condition abroad under the chewable tablet of the different disintegrating agent consumptions of table 8
The chewable tablet of table 9 different material particle diameter is the dissolution under standard leaching condition abroad
In oral solid formulation preparation process, the particle diameter of raw material, granularity, crystal formation, the disintegrating agent consumption in prescription can cause the change of final sample dissolution.For the such crude drug of Menglusitena, disintegrating agent consumption, raw material particle size in its prescription affect preparation stripping behavior, and the present invention selects different-grain diameter, different disintegrating agent consumption to make preparation, investigates the difference of these preparation stripping behaviors.
From table 7-table 9 and Fig. 4-Fig. 6, existing dissolution determination method is the in the situation that of raw material particle size change and the change of crucial supplementary product consumption, and prepared sample still shows similar stripping behavior, and dissolving-out method does not have certain differentiation power.
Although above the present invention is described in detail with a general description of the specific embodiments, on basis of the present invention, can make some modifications or improvements it, this will be apparent to those skilled in the art.Therefore, these modifications or improvements, all belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (10)
1. a Menglusitena chewable tablet, is characterized in that: by the raw material that comprises following weight portion, be prepared from:
It is that solvent is mixed with the solution that quality percentage composition is 6-8% that described hydroxypropyl cellulose adopts water.
2. Menglusitena chewable tablet according to claim 1, is characterized in that: by the raw material that comprises following weight portion, be prepared from:
3. the preparation method of the Menglusitena chewable tablet described in claim 1 or 2, is characterized in that, comprises the following steps:
(1), under the condition of lucifuge, Menglusitena, magnesium stearate, red ferric oxide, mannitol, microcrystalline Cellulose, cross-linking sodium carboxymethyl cellulose, A Siba is sweet, cherry essence sieves respectively;
(2) take hyprolose and add purified water, be stirred to and dissolve completely, being mixed with quality percentage composition is 6-8% aqueous solution;
(3) by the Menglusitena having sieved, mannitol, microcrystalline Cellulose, partial cross-linked sodium carboxymethyl cellulose, red ferric oxide mix homogeneously in wet granulation equipment, the hyprolose aqueous solution that adds step (2) to be mixed with, wet granulation, granulate;
(4) wet granular step (3) being made, through fluidized drying, makes moisture Control below 1.5%, granulate;
(5) add cross-linking sodium carboxymethyl cellulose, cherry essence, the A Siba of surplus sweet, magnesium stearate mix after tabletting.
4. preparation method according to claim 4, is characterized in that: the 40-60% that the addition of the described cross-linking sodium carboxymethyl cellulose of step (3) is all cross-linking sodium carboxymethyl celluloses, preferably 50%.
5. the assay method of Menglusitena chewable tablet dissolution described in claim 1 or 2, according to two appendix XC dissolution method the second methods of Chinese Pharmacopoeia version in 2010, it is characterized in that: the sodium lauryl sulphate phosphate buffered solution of mass volume ratio 0.4-0.6% of take is dissolution medium.
6. the assay method of dissolution according to claim 5, is characterized in that, comprises the following steps:
(1) getting 5mg chewable tablet, to take the sodium lauryl sulphate phosphate buffered solution that 900ml mass volume ratio is 0.4-0.6% be dissolution medium, rotating speed is per minute 50 to turn, during respectively at 5min, 10min, 15min, 20min, 30min, sample 10ml, filter, get subsequent filtrate as need testing solution; Separately get reference substance 15mg, add dissolve with methanol and be diluted to 50ml, after shaking up, get 2ml solution, add mass volume ratio 0.4-0.6% sodium lauryl sulphate phosphate buffered saline(PBS) dissolved dilution to 100ml, in contrast product solution;
(2) get need testing solution and the reference substance solution employing high performance liquid chromatography of step (1) gained, take phenyl bonded silica gel as filler, take 0.2% trifluoroacetic acid aqueous solution and 0.2% trifluoroacetic acid acetonitrile solution by volume as the mixed solution of 1: 1 is mobile phase, by external standard method with calculated by peak area dissolution.
7. the assay method of dissolution according to claim 6, it is characterized in that: step (1) is got 5mg chewable tablet, and to take the sodium lauryl sulphate phosphate buffered solution that 900ml mass volume ratio is 0.5% be dissolution medium, rotating speed is per minute 50 to turn, during respectively at 5min, 10min, 15min, 20min, 30min, sample 10ml, filter, get subsequent filtrate as need testing solution; Separately get reference substance 15mg, add dissolve with methanol and be diluted to 50ml, after shaking up, get 2ml solution, add mass volume ratio 0.5% sodium lauryl sulphate phosphate buffered saline(PBS) dissolved dilution to 100ml, in contrast product solution.
8. the assay method of dissolution according to claim 6, is characterized in that: the described reference substance of step (1) is chosen a kind of in montelukast hexanamine salt, montelukast acid, Menglusitena.
9. the assay method of dissolution according to claim 6, is characterized in that: when step (2) adopts high performance liquid chromatography, flow velocity is 0.8-1.0ml/min; Column temperature is 48-52 ℃, and sampling volume is 48-52 μ l.
10. the application of the assay method of dissolution described in claim 5-9 any one.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410424525.8A CN104146975A (en) | 2014-08-26 | 2014-08-26 | Montelukast sodium chewable tablet, preparation method and determination method of dissolution rate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410424525.8A CN104146975A (en) | 2014-08-26 | 2014-08-26 | Montelukast sodium chewable tablet, preparation method and determination method of dissolution rate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104146975A true CN104146975A (en) | 2014-11-19 |
Family
ID=51872744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410424525.8A Pending CN104146975A (en) | 2014-08-26 | 2014-08-26 | Montelukast sodium chewable tablet, preparation method and determination method of dissolution rate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104146975A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287413A (en) * | 2015-10-23 | 2016-02-03 | 南京泽恒医药技术开发有限公司 | Chewable tablet containing montelukast sodium and preparation method of chewable tablet |
| CN105456213A (en) * | 2015-12-31 | 2016-04-06 | 鲁南贝特制药有限公司 | Montelukast sodium tablet |
| CN105616368A (en) * | 2016-01-22 | 2016-06-01 | 山东新时代药业有限公司 | Montelukast sodium tablet and preparation method thereof |
| CN108186594A (en) * | 2018-03-09 | 2018-06-22 | 上海安必生制药技术有限公司 | A kind of Montelukast sodium chewable tablet and preparation method thereof |
| CN109833302A (en) * | 2017-11-29 | 2019-06-04 | 扬子江药业集团有限公司 | A kind of stable Montelukast sodium chewable tablet and preparation method thereof |
| CN109900823A (en) * | 2019-03-12 | 2019-06-18 | 康诚科瑞医药研发（武汉）有限公司 | The quantitative detecting method of montelukast in a kind of human plasma |
| CN111000813A (en) * | 2020-01-06 | 2020-04-14 | 国药集团致君（深圳）坪山制药有限公司 | Montelukast sodium chewable tablet and preparation method thereof |
| CN112034118A (en) * | 2020-07-29 | 2020-12-04 | 北京诺康达医药科技股份有限公司 | Method for rapidly detecting dissolution rate of solid preparation |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239450A (en) * | 2012-02-07 | 2013-08-14 | 齐鲁制药有限公司 | Rapidly-dissolving and stabile montelukast oral solid preparation and preparation method thereof |
-
2014
- 2014-08-26 CN CN201410424525.8A patent/CN104146975A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239450A (en) * | 2012-02-07 | 2013-08-14 | 齐鲁制药有限公司 | Rapidly-dissolving and stabile montelukast oral solid preparation and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| PRIYANKA ETAL: "FORMULATION DEVELOPMENT AND EVALUATION OF MONTELUKAST SODIUM CHEWABLE TABLETS", 《JOURNAL OF CHEMICAL AND PHARMACEUTICAL SCIENCES》, vol. 6, no. 1, 31 March 2013 (2013-03-31), pages 35 - 40 * |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287413A (en) * | 2015-10-23 | 2016-02-03 | 南京泽恒医药技术开发有限公司 | Chewable tablet containing montelukast sodium and preparation method of chewable tablet |
| CN105456213A (en) * | 2015-12-31 | 2016-04-06 | 鲁南贝特制药有限公司 | Montelukast sodium tablet |
| CN105616368A (en) * | 2016-01-22 | 2016-06-01 | 山东新时代药业有限公司 | Montelukast sodium tablet and preparation method thereof |
| CN109833302A (en) * | 2017-11-29 | 2019-06-04 | 扬子江药业集团有限公司 | A kind of stable Montelukast sodium chewable tablet and preparation method thereof |
| CN108186594A (en) * | 2018-03-09 | 2018-06-22 | 上海安必生制药技术有限公司 | A kind of Montelukast sodium chewable tablet and preparation method thereof |
| CN108186594B (en) * | 2018-03-09 | 2021-08-13 | 上海安必生制药技术有限公司 | Montelukast sodium chewable tablet and preparation method thereof |
| CN109900823A (en) * | 2019-03-12 | 2019-06-18 | 康诚科瑞医药研发（武汉）有限公司 | The quantitative detecting method of montelukast in a kind of human plasma |
| CN111000813A (en) * | 2020-01-06 | 2020-04-14 | 国药集团致君（深圳）坪山制药有限公司 | Montelukast sodium chewable tablet and preparation method thereof |
| CN112034118A (en) * | 2020-07-29 | 2020-12-04 | 北京诺康达医药科技股份有限公司 | Method for rapidly detecting dissolution rate of solid preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104146975A (en) | Montelukast sodium chewable tablet, preparation method and determination method of dissolution rate | |
| TWI600665B (en) | Low-substituted hydroxypropyl cellulose powder and its production method | |
| CN103239450B (en) | Rapidly-dissolving and stabile montelukast oral solid preparation and preparation method thereof | |
| CN103494785B (en) | Montelukast sodium chewable tablet and preparation method thereof | |
| KR101527254B1 (en) | Low-substituted hydroxypropylcellulose and solid preparation comprising the same | |
| CN101756917A (en) | Donepezil hydrochloride orally disintegrating tablet and preparation method thereof | |
| CN105412036A (en) | Brexpiprazole orally disintegrating tablets | |
| CN104958764A (en) | Tilmicosin smell masking preparation and preparing method thereof | |
| CN105147614B (en) | A kind of solid pharmaceutical preparation and preparation method thereof including BIBW 2992MA2 | |
| CN104887633A (en) | Rivaroxaban tablets and preparation method thereof | |
| KR101834559B1 (en) | Solid composite formulation for oral administration comprising ezetimibe and rosuvastatin | |
| JP2020518611A (en) | Compositions with improved water solubility and bioavailability | |
| CN112603900A (en) | Solid preparation containing [ (4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl) -amino ] -acetic acid | |
| CN104666262A (en) | Rivaroxaban tablet | |
| CN103263395A (en) | Telmisartan tablet preparation and preparation method thereof | |
| CN101703448A (en) | Direct compression process for cefuroxime axetil dispersible tablets | |
| CN105287413A (en) | Chewable tablet containing montelukast sodium and preparation method of chewable tablet | |
| JP4774739B2 (en) | Kampo extract-containing tablet composition and method for producing the same | |
| CN103202817B (en) | Preparation method for mannitol grains capable of being directly pressed | |
| CN111000813B (en) | Montelukast sodium chewable tablet and preparation method thereof | |
| CN102106824B (en) | Eszopiclone solid preparation and preparation method thereof | |
| CN104098489A (en) | Micronized glibenclamide and composition thereof | |
| CN103006604A (en) | Cefuroxime axetil tablets and preparation method thereof | |
| CN107375938A (en) | A kind of adhesive of aminoglucose hydrochloride, tablet and preparation method thereof | |
| CN113599366A (en) | Tenofovir disoproxil fumarate granules and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20141119 |